Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 796-801

  Qu, Li Shuai ^a   Jin, Fei ^a   Huang, Xiao Wu ^a   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

hepatitis B virus; hepatocellular carcinoma; interferon ; recurrence

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGUS VARICES; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649655583     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21741     Document Type: Article

References (33)

1. Llovet JM, Burroughs A, Bruix J,: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Takayama T, Makuuchi M, Hirohashi S, et al.: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28: 1241-1246.
3. Zhang BH, Yang BH, Tang ZY,: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
4. Adachi E, Maeda T, Matsumata T, et al.: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108: 768-775.
5. Shah SA, Cleary SP, Wei AC, et al.: Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery 2007; 141: 330-339.
6. Ohkubo T, Yamamoto J, Sugawara Y, et al.: Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000; 191: 657-660.
7. Tung-Ping Poon R, Fan ST, Wong J,: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24. (Pubitemid 30456545)
8. Poon RT, Fan ST, Ng IO, et al.: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
9. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356: 802-807.
10. von Marschall Z, Scholz A, Cramer T, et al.: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-448.
11. Wang L, Wu WZ, Sun HC, et al.: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-594.
12. Lin SM, Sheen IS, Chien RN, et al.: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975.
13. Mazzella G, Accogli E, Sottili S, et al.: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-147.
14. Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
15. Kubo S, Nishiguchi S, Hirohashi K, et al.: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967.
16. Kubo S, Nishiguchi S, Hirohashi K, et al.: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422. (Pubitemid 34595504)
17. Sun HC, Tang ZY, Wang L, et al.: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
18. Lin SM, Lin CJ, Hsu CW, et al.: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376-382.
19. Mazzaferro V, Romito R, Schiavo M, et al.: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
20. Lo CM, Liu CL, Chan SC, et al.: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
21. Uenishi T, Nishiguchi S, Tanaka S, et al.: Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008; 98: 358-362.
22. Imamura H, Matsuyama Y, Tanaka E, et al.: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
23. Edmondson HA, Steiner PE,: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
24. Couinaud C,: The anatomy of the liver. Ann Ital Chir 1992; 63: 693-697.
25. Kudo M,: Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008; 75: 30-41.
26. Wu JC, Huang YH, Chau GY, et al.: Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897.
27. Chen YJ, Yeh SH, Chen JT, et al.: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431-440.
28. Wang L, Tang ZY, Qin LX, et al.: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000; 32: 43-48.
29. Nakaji M, Yano Y, Ninomiya T, et al.: IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389-397.
30. Sun HC, Zhang W,: Re: Interferon: The magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 2008; 247: 900, author reply 900-901.
31. Ishikawa T,: Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2010; 16: 2463-2467.
32. Belghiti J, Panis Y, Farges O, et al.: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214: 114-117.
33. Sumie S, Kuromatsu R, Okuda K, et al.: Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375-1382.